Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 28 July 2017 | By Michael Mezher
The European Medicines Agency (EMA) on Friday released a concept paper for public consultation outlining issues it plans to address in an upcoming guideline on the challenges in developing companion diagnostics for personalized medicines.
Specifically, EMA says its guideline will address the development of companion diagnostics for precision medicines in the clinical development and post-approval phases, and will include a glossary defining terms used in the guideline as well as in the IVDR.
Once adopted, EMA says the guideline will replace its existing reflection paper on the co-development of pharmacogenomics markers and assays released in 2010.
According to the agency, the decision to use a personalized medicine hinges on the use of companion diagnostics to determine whether a patient will benefit from a medicine, or alternatively whether the patient is at a higher risk for adverse reactions to the treatment.
"It is very important to clarify how evidence to support the validation of a companion diagnostic can be generated during the development of a medicine," EMA says.
However, EMA is not directly involved in authorizing companion diagnostics, as they are treated as in vitro diagnostic medical devices in the EU and can be marketed after being CE marked.
But, the agency says the new EU in vitro diagnostic regulation (IVDR) "foresees cooperation between medicines regulators and EU notified bodies … in the evaluation of new companion diagnostics to obtain the CE label."
According to EMA, drug and diagnostic developers oftentimes begin work on their products independently, and come together "only superficially towards the end" of the development phase, which the agency says is not ideal.
EMA also says it hopes developing guidance in this area will lead to more "close knit development programmes."
EMA, Concept Paper
Tags: Companion Diagnostics, CDx, Precision Medicine, Biomarkers
Regulatory Focus newsletters
All the biggest regulatory news and happenings.